XBIvsSBIOETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) belongs to the US Health Care segment. ALPS Medical Breakthroughs ETF (SBIO) is part of the Tomorrow's Treatments segment. XBI's top 2 sector exposures are Healthcare and Finance. In contrast, SBIO's top sector exposures are Healthcare and Non-Corporate. XBI is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.5% for SBIO. XBI is up 22.77% year-to-date (YTD) with +$853M in YTD flows. SBIO performs worse with 4.3% YTD performance, and +$62M in YTD flows. Run a side-by-side ETF comparison of XBI and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/23/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI SBIO | -3.93%-11.00% | -1.72%-17.10% | +22.77%+4.30% | +39.61%+26.73% | +130.21%+130.96% | +20.98%+19.37% |
| Flows | XBI SBIO | +$229M-$10M | +$343M+$21M | +$853M+$62M | +$1.24B+$79M | +$276M+$45M | +$1.96B+$6M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI SBIO | +30.32%+31.85% | +29.02%+32.35% | +28.46%+31.52% | +33.06%+34.22% |
| Max drawdown | XBI SBIO | -14.89%-29.19% | -14.89%-29.19% | -32.94%-42.12% | -53.28%-52.50% |
| Max drawdown duration | XBI SBIO | 65d65d | 65d65d | 331d331d | 1622d1479d |
Trading data
XBI | SBIO | |
Last sale 10/23/2026 at 1:30 PM | $149.54 | $53.38 |
| Previous close 10/22/2026 | $151.64 | $54.55 |
| Consolidated volume 10/22/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/23/2026 at 1:30 PM
Live
Closed
XBI | SBIO | |
|---|---|---|
| Last price | $149.54 | $53.38 |
| 1D performance | -1.38% | -2.14% |
| AuM | $10.36 B | $183.99 M |
| E/R | 0.35% | 0.5% |
Characteristics
XBI | SBIO | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | ALPS |
| Benchmark | S&P Biotechnology Select Industry Index | S-Network Medical Breakthroughs Index |
| N° of holdings | 149 | 104 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | December 30, 2014 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.53%
Other
4.47%
SBIO
USA
89.31%
Other
10.69%
Sectors
XBI
Healthcare
99.18%
Other
0.82%
SBIO
Healthcare
100.01%
Other
-0.01%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
21.91%
SBIO
Total weight of top 15 holdings out of 15
41.55%
Top 15 holdings
Data as of August 31, 2026
XBI
Moderna, Inc.
2.81%
Twist Bioscience Corp.
1.89%
Apogee Therapeutics, Inc.
1.50%
Kymera Therapeutics, Inc.
1.40%
Halozyme Therapeutics, Inc.
1.39%
Natera, Inc.
1.37%
Praxis Precision Medicines, Inc.
1.34%
Oruka Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.31%
Travere Therapeutics, Inc.
1.30%
Protagonist Therapeutics, Inc.
1.28%
Dianthus Therapeutics, Inc.
1.27%
CG Oncology, Inc.
1.26%
Vaxcyte, Inc.
1.23%
Erasca, Inc.
1.23%
SBIO
Crinetics Pharmaceuticals, Inc.
4.60%
Apogee Therapeutics, Inc.
4.29%
CG Oncology, Inc.
3.41%
Travere Therapeutics, Inc.
3.16%
Xenon Pharmaceuticals, Inc.
2.99%
Dianthus Therapeutics, Inc.
2.96%
Oruka Therapeutics, Inc.
2.87%
ACADIA Pharmaceuticals, Inc.
2.54%
Edgewise Therapeutics, Inc.
2.31%
Definium Therapeutics, Inc.
2.23%
Dyne Therapeutics, Inc.
2.16%
Veradermics, Inc.
2.11%
Relay Therapeutics, Inc.
2.05%
Denali Therapeutics, Inc.
1.94%
Amylyx Pharmaceuticals, Inc.
1.93%
Frequently asked questions about XBI and SBIO
How have the XBI and SBIO ETFs performed in 2026?
As of October 23, 2026, XBI is up 22.77% year-to-date (YTD), while SBIO has returned 4.3%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or SBIO?
Year-to-date, the XBI ETF saw +$853M in flows, compared to +$62M for SBIO.
Which ETF is more volatile: XBI or SBIO?
Over the past year, XBI had a volatility of 29.02%, while SBIO experienced 32.35%.
Which ETF is bigger: XBI or SBIO?
As of October 23, 2026, XBI holds $10.36 B in assets under management (AUM), while SBIO manages $183.99 M.
What sectors do the XBI and SBIO ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, SBIO focuses on Healthcare.
What are the top holdings of the XBI ETF and SBIO ETF?
XBI top holdings include Moderna, Inc., Twist Bioscience Corp. and Apogee Therapeutics, Inc.. SBIO holds in its top three: Crinetics Pharmaceuticals, Inc., Apogee Therapeutics, Inc. and CG Oncology, Inc..
Which ETF is more diversified: XBI or SBIO?
XBI holds 152 securities with 21.91% of its assets in the top 15. SBIO has 104 securities and a top 15 weight of 41.55%.
Advertisement
Latest news about XBI & SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
SBIO
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
SBIO
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
